Skip to content

Investing in Innovative

cannabis Science

Emerald Health Therapeutics is a cannabis company committed to creating new consumer experiences with distinct recreational, medical
and wellness-oriented cannabis and non-cannabis products, with an emphasis on life science-based innovation and product excellence.

Emerald is uniquely positioned to pursue multiple growth options with a clear focus on profitability, sustainability and value creation for its shareholders.

Investor Resources

Investor Presentation

November 03, 2020

Fact Sheet

November 03, 2020

Stock Information

Pricing delayed by 20 minutes.

Our Facilities

Strongly focused on consumer preferences and production excellence, Emerald’s fully operational facilities are purposefully designed to provide defined-scale, high quality dried flower to the premium market segment and to support the development of differentiated, high-margin cannabis derivative products.

Emerald Richmond

Emerald’s Richmond Organic-certified greenhouse operation focuses on producing, processing, and distributing premium segment targeted cannabis products. Its 78,000 sq. ft. purpose-built greenhouse facility is in full production, while a second 78,000 sq. ft greenhouse is near completion. With its newly issued standard processing license, the site is now able to process consumer-ready dried product formats and is well-positioned to support the manufacturing and packaging products derived from cannabis, that advance through its new product development efforts.

Emerald Victoria

Victoria, Emerald’s wholly-owned 10,000 square foot facility in Victoria, BC, includes a 2000 square foot indoor grow and a 6000 square foot packaging and extraction operation. Victoria is Emerald’s Medicinal Cannabis hub, where customer relations, packaging and distribution take place. Victoria’s R&D lab is focused on plant genetics, breeding and next generation cannabis products development.


Verdélite, Emerald’s wholly-owned 88,000 square feet indoor grow facility in Saint-Eustache, QC. Emerald entered into a sales agreement to sell all verdélite assets. Upon closing Emerald to receive ~$22M.

Our Strategic Partners

Large Scale extraction

International Distribution

IP and Product development

Stay updated

Join our investor newsletter to receive the latest news and updates from Emerald Health Therapeutics.

Rebecca Wong

Vice President, Quality and Regulatory Affairs

Ms. Wong has more than 25 years of managerial experience in quality assurance and quality control spanning research, preclinical, clinical, and commercial phases for pharmaceuticals, combination products, biologicals and medical devices. Before joining Emerald, she was the Executive Director of Quality Assurance at Novelion Therapeutics (formerly QLT Inc.), where she was the head of quality assurance, validation, compliance auditing, document management, and GxP training departments. Ms. Wong previously worked for life science companies including MDS Nordion, Cangene Corporation, and Biomira Inc. Specializing in microbiology, she earned a BSc from the University of Alberta.

Jenn Hepburn

Chief Financial Officer

Ms. Hepburn has over a decade of experience in accounting and finance and is an experienced manager of privately and publicly traded manufacturing and mining businesses operating in Canada and the USA. Prior to joining Emerald, Ms. Hepburn was the Director of Finance and Administration at bioLytical Laboratories Inc., a medical diagnostics manufacturer. Before that, she held controller positions at junior gold and silver mining companies Northern Vertex Mining Corp., Kootenay Silver Inc. and Theia Resources Ltd. Ms. Hepburn earned a BBA from Simon Fraser University and her certification from the Certified Management Accountants of British Columbia.


President & Chief Executive Officer

Mr. Bandali’s expertise in global operations, strategy development, driving innovation, M&A, and investment management has been developed over a 25-year career in the life sciences sector spanning contract clinical and research services, analytical instrumentation, lab services and venture capital.

He holds an Advanced Management Program Degree from Harvard Business School, a Master of Business Administration from McGill University, and a Bachelor of Science from the University of British Columbia. He is an innovative business leader who has built strategic and operating plans that have resulted in rapid growth and significant profitability enhancement. He has managed businesses and operations with a global footprint and has led teams of over 900 people.

Mr. Bandali’s previous experience includes serving as President, Early Phase Clinical Services and Translational Science, Syneos Health; President, Early Stage Development, as well as Chief Innovation Officer, inVentiv Health Clinical; Senior Vice President, Strategy and Business Development, AB Sciex and Molecular Devices (part of Danaher Corporation); Senior Vice President, Strategy, Legal and Corporate Development, MDS Analytical Technologies; and Vice President and General Manager, Global Early Stage Development, MDS Pharma Services. He was also Venture Partner and Vice President at MDS Capital and has served on the boards of private and public companies.